Visus Therapeutics

Visus Therapeutics, founded with a mission to revolutionize eye care, focuses on developing innovative treatments for presbyopia. Their core product, BRIMOCHOL PF™, is a presbyopia-correcting eye drop designed to provide up to eight hours of vision improvement. As a clinical-stage pharmaceutical company, Visus Therapeutics aims to address the unmet needs in ophthalmology, particularly targeting the aging population affected by presbyopia.

Key figures associated with Visus Therapeutics include experienced professionals and investors from the pharmaceutical and healthcare sectors. The company has achieved significant milestones, including positive topline clinical data from their Phase 3 pivotal BRIO-I trial. Visus Therapeutics' advancements have the potential to significantly impact the quality of life for individuals with presbyopia, positioning them as leaders in ophthalmic innovation.